MedPath

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults

Phase 1
Completed
Conditions
COVID-19
Interventions
First Posted Date
2021-03-01
Last Posted Date
2025-05-16
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
81
Registration Number
NCT04776317
Locations
🇺🇸

The Hope Clinic of Emory University, Decatur, Georgia, United States

🇺🇸

Baylor College of Medicine, Houston, Texas, United States

🇺🇸

Saint Louis University Center for Vaccine Development, Saint Louis, Missouri, United States

and more 1 locations

Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies

Recruiting
Conditions
Influenza
Coronavirus
Respiratory Virus
First Posted Date
2021-02-26
Last Posted Date
2025-03-30
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
1000
Registration Number
NCT04772170
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations

Phase 2
Completed
Conditions
Allergic Reaction
Mast Cell Disorder
COVID-19
SARS-CoV Infection
Interventions
Biological: Moderna COVID-19 Vaccine
Biological: Pfizer-BioNTech COVID-19 Vaccine
Biological: Placebo
First Posted Date
2021-02-21
Last Posted Date
2023-12-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
746
Registration Number
NCT04761822
Locations
🇺🇸

NorthShore University HealthSystem, Dermatology Clinical Trials Unit, Skokie, Illinois, United States

🇺🇸

Stanford Medicine, Sean N. Parker Center for Allergy & Asthma Research, Stanford, California, United States

🇺🇸

University of Iowa Health Care, Iowa City, Iowa, United States

and more 26 locations

Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination

Phase 2
Completed
Conditions
Gonorrhoea
Interventions
First Posted Date
2021-01-25
Last Posted Date
2024-11-05
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
52
Registration Number
NCT04722003
Locations
🇺🇸

The Hope Clinic of Emory University, Decatur, Georgia, United States

Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia

Active, not recruiting
Conditions
Malaria
First Posted Date
2021-01-12
Last Posted Date
2025-05-20
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
396
Registration Number
NCT04704674
Locations
🇱🇷

National Public Health Institute of Liberia (NPHIL), Fleh-la, Liberia

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males

First Posted Date
2020-12-31
Last Posted Date
2025-05-20
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
9
Registration Number
NCT04692077
Locations
🇺🇸

University of Colorado Denver ATN CRS, Aurora, Colorado, United States

🇺🇸

John H. Stroger Jr. Hosp. of Cook County ATN CRS, Chicago, Illinois, United States

🇺🇸

The Fenway Institute ATN CRS, Boston, Massachusetts, United States

and more 1 locations

Anthrax AV7909 Liquid vs Lyophilized

Phase 1
Completed
Conditions
Anthrax
Anthrax Immunisation
Interventions
First Posted Date
2020-12-09
Last Posted Date
2024-12-19
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
41
Registration Number
NCT04660201
Locations
🇺🇸

University of Maryland, School of Medicine, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States

Malaria Transmission in Humans and Mosquitoes at the Area of Sabou, Burkina Faso

Completed
Conditions
Malaria
First Posted Date
2020-12-03
Last Posted Date
2025-05-20
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
608
Registration Number
NCT04650815
Locations
🇧🇫

CMAMK, Sabou, Burkina Faso

🇧🇫

GRAS, Sabou, Burkina Faso

Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection

Phase 1
Active, not recruiting
Conditions
Infectious Mononucleosis
EBV
Epstein-Barr Virus Infection
Interventions
Biological: EBV gp350-Ferritin Vaccine
Other: Matrix-M1
First Posted Date
2020-11-27
Last Posted Date
2025-04-27
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
83
Registration Number
NCT04645147
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Adaptive COVID-19 Treatment Trial 4 (ACTT-4)

Phase 3
Completed
Conditions
COVID-19
Interventions
First Posted Date
2020-11-23
Last Posted Date
2022-06-28
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
1010
Registration Number
NCT04640168
Locations
🇺🇸

Cedars Sinai Medical Center, West Hollywood, California, United States

🇺🇸

University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States

🇺🇸

University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States

and more 69 locations
© Copyright 2025. All Rights Reserved by MedPath